CN101259138A - Anti-inflammation and ease-pain composition topical application for animal kinematic scheme part - Google Patents
Anti-inflammation and ease-pain composition topical application for animal kinematic scheme part Download PDFInfo
- Publication number
- CN101259138A CN101259138A CNA2007101053345A CN200710105334A CN101259138A CN 101259138 A CN101259138 A CN 101259138A CN A2007101053345 A CNA2007101053345 A CN A2007101053345A CN 200710105334 A CN200710105334 A CN 200710105334A CN 101259138 A CN101259138 A CN 101259138A
- Authority
- CN
- China
- Prior art keywords
- antiinflammatory
- compositions
- hydrogel
- animal
- arnica montana
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to an anti-inflammatory and pain-killing composition that can be partially used; the composition consists of the following ingredients by weight percentage: about 0.01-3 percent of hyaluronic acid, about 0.5-7 percent of extract of arnica glycol, about 2-10 percent of any hydrogel soluble non-steroidal anti-inflammatory agent, and about 70-95 percent of hydrogel.
Description
Technical field
The present invention relates to a kind of antiinflammatory and analgesic composition, be applied to the epidermis position of the muscle, joint, tendon and the ligament pain that cause by pathological changes, contusion and wound.
Background technology
Prior art comprises a large amount of compositionss that exist with ointment, cream, spray or foam form, can relax above-mentioned specific pain and can be significantly or treatment causes pain to a certain extent the cause of disease.Be called such as name
Commodity, wherein active component is respectively, diclofenac diethyl ammonium, diethylamide salicylate, ketoprofen, ketoprofen lysinate.Other active component relevant with described purpose that many other products adopt pharmacopeia to comprise also are used for identical purpose.JP11 279 065 discloses a kind of antiinflammatory product of topical solution form, contains two kinds of water solublity antiinflammatories and hyaluronic acid, and antiinflammatory wherein is a kind of to be the steroid type, and another kind is the on-steroidal type.
Existing compositions with analgesia and antiinflammatory action contains a kind of active component mostly, and it can not be carried to patient part well.So the effect duration of compositions is short and can not be diffused into region of interest.In addition, these known compositionss have undesirable effect, and this is because to slight or significant allergy of one or more components and allergy.
Summary of the invention
The present composition has been avoided above-mentioned restriction and shortcoming, and following other advantages that will describe are provided.
The present composition comprise hyaluronate, arnica montana extract as active component and dissolve in gel non--(FANS-is methyl salicylate for example for the steroid antiinflammatory, diclofenac, the ketoprofen lysinate), and the excipient of active component, this excipient is can provide ultrasonic and medicinal hydrogel electron transport, can give the best physical property of compositions and will be known as the gel type of hydrogel hereinafter.
Hyaluronic acid as antiinflammatory and chemoattractant by for a long time known, usually and be successfully used to injectable liquid and treat osteoarthritis, gonarthrosis, wound and burn are used for cosmetic surgery and culture, also can be used as the component of a usefulness.In the present composition, hyaluronic acid preferably uses with hyaluronate sodium, is dissolved in the exactly essential pure water before the preparation compositions.
People have known for a long time following effect: arnica montana is used for the treatment of the symptom of wound consequence and similar " after the wound "; FANS is used for the treatment of pain and as antiinflammatory; Hydrogel is as the excipient that is used for the medicine of epidermis.
Three kinds of active component and hydrogel combination in the present composition, these four kinds of components are with the ratio of suggestion, form liquid and gel-like prod, its epidermis absorbs the pain of alleviating joint and bone flesh (osteomuscular) position soon and significantly, reduce possible inflammation, absorb possible exosmose serosity or the blood that cause by wound or contusion.
Such effect mainly is owing to hyaluronic antiinflammatory and chemotaxis, also because its significant hydrophilic.The latter is expanded the hole of basement membrane, is aided with the height delivery effect that hydrogel provides, and makes itself and other two kinds of antiinflammatory and analgesia component can penetrate patient part fast.In addition, in life-time service, also do not put down in writing the undesirable effect and the anaphylactic reaction of this compositions.
The specific embodiment
First prescription of said composition confirms that by the test to a lot of people very obvious effect is arranged, and the said composition of 100g contains by weight:
Hyaluronate sodium, about 0.01-3.00%,
Arnica montana ethylene glycol extraction thing (glycolic extract), about 0.5-7.0%,
The water soluble gel is non-arbitrarily-the steroid antiinflammatory, and about 2-10%,
Hydrogel, about 70-95%,
Pure water, about 0.2%,
As everyone knows, have much non--steroid antiinflammatory, the inventor proves each antiinflammatory, as long as it is dissolved in hydrogel, can be used for these compositionss with the ratio of about 2-10%, and purpose provides the effect of said composition expection.The most effective antiinflammatory is a methyl salicylate among known the present invention.
The prescription of said composition is proved to be the most effective in alternative a large amount of percentage tests of a large amount of people's test and four kinds of compositions, following prescription can reach the set goal by weight:
-hyaluronate sodium is about 0.2%,
-pure water is about 0.2%,
-arnica montana ethylene glycol extraction thing is about 2%,
-methyl salicylate is about 5%,
-hydrogel about 92.6%.
Claims (5)
1. an antiinflammatory and analgesic composition that is applied topically to animal kinematic scheme part, comprise non--steroid antiinflammatory and hyaluronic acid and arnica montana as effective ingredient, be blended in the product that is suitable for carrying active principles, wherein compositions is the non-steroidal anti-inflammatory agents of hyaluronate, arnica montana ethylene glycol extraction thing and water soluble gel and as the mixture of the hydrogel of carrying active principles.
2. according to the compositions of claim 1, comprise by weight:
Hyaluronate sodium, about 0.01-3.00%,
Arnica montana ethylene glycol extraction thing, about 0.5-7.0%,
The water soluble gel is non-arbitrarily-the steroid antiinflammatory, and about 2-10%,
Hydrogel, approximately 70-95% and
Pure water, about 0.2%.
3. according to the compositions of claim 1, wherein the water soluble gel is non--and the steroid antiinflammatory is a methyl salicylate.
4. a portion is applied to the antiinflammatory and the analgesic composition of animal kinematic scheme part, comprise non--steroid antiinflammatory and hyaluronic acid and arnica montana as effective ingredient, be blended in the product that is suitable for carrying active principles, wherein compositions is made up of following composition by weight:
-hyaluronate sodium, about 0.2%,
-pure water, about 0.2%,
-arnica montana ethylene glycol extraction thing, about 2%,
-methyl salicylate, about 5% and
-hydrogel, about 92.6%.
5. according to the compositions of claim 2, wherein the water soluble gel is non--and the steroid antiinflammatory is a methyl salicylate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101053345A CN101259138A (en) | 2007-03-07 | 2007-03-07 | Anti-inflammation and ease-pain composition topical application for animal kinematic scheme part |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101053345A CN101259138A (en) | 2007-03-07 | 2007-03-07 | Anti-inflammation and ease-pain composition topical application for animal kinematic scheme part |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101259138A true CN101259138A (en) | 2008-09-10 |
Family
ID=39959969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007101053345A Pending CN101259138A (en) | 2007-03-07 | 2007-03-07 | Anti-inflammation and ease-pain composition topical application for animal kinematic scheme part |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101259138A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107693560A (en) * | 2017-09-13 | 2018-02-16 | 冯威 | A kind of pharmaceutical compositions with analgesia function |
-
2007
- 2007-03-07 CN CNA2007101053345A patent/CN101259138A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107693560A (en) * | 2017-09-13 | 2018-02-16 | 冯威 | A kind of pharmaceutical compositions with analgesia function |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7052715B2 (en) | Alcohol-free transdermal analgesic composition and processes for manufacture and use thereof | |
| EP2373346B1 (en) | Ibuprofen for topical administration | |
| JP6961055B2 (en) | Homeopathic Therapeutic Methods and Compositions | |
| CN109568267B (en) | Freezing analgesic aerosol and preparation method thereof | |
| WO2011044381A1 (en) | Pain relief composition, system and method | |
| JP2012501348A (en) | Homeopathic treatment | |
| CN1859918A (en) | Methods for treating acute and overuse sprain and strain using hyaluronic acid | |
| US20050232980A1 (en) | Transdermal chondroitin and glucosamine delivery system and method of use | |
| US20140348873A1 (en) | Urea-Silicone Gel for Hyperkeratosis Treatment | |
| CN101259138A (en) | Anti-inflammation and ease-pain composition topical application for animal kinematic scheme part | |
| RU2268052C2 (en) | Agent for treatment of inflammatory and degenerative joint disease (variants), method for treatment of inflammatory and degenerative joint disease (variants) and device for delivery of medicinal agent to damaged site | |
| JP2012092067A (en) | Nonsteroidal anti-inflammatory analgesic agent for external use | |
| US20240024273A1 (en) | Topical administration of 2-(diethylamino)ethyl 2-(4-isobutylphenyl)proprionate for treatment of diseases | |
| US20120070507A1 (en) | Compositions and Methods for the Treatment of Soft Tissue Injury | |
| CA2785116C (en) | A combination for the treatment of osteoarthritis | |
| RU2159113C1 (en) | Agent with antiinflammatory, antiseptic, and regenerating activity | |
| JP2005330199A (en) | Joint cream | |
| US20080193576A1 (en) | Antiphlogistic and analgesic composition for topical use in a region of an animal locomotive system | |
| CN101837068B (en) | Preparation process of zanthoxylum oil spray and application thereof | |
| WO2017181977A1 (en) | Mussel adhesive protein product and use thereof for inhibiting soft tissue inflammation | |
| CN108653262B (en) | Ketoprofen external medicine and preparation method and application thereof | |
| EP1818045B1 (en) | Antiphlogistic and analgesic compound for topical use in an area of an animal locomotive system | |
| ES2664930T3 (en) | Adjuvant composition for topical use | |
| CN1965939A (en) | Externally applied formulation for treating skin amyloidosis | |
| JP2010528065A (en) | Anti-inflammatory and analgesic compositions for topical use in the field of animal motor systems |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20080910 |